ZADAXIN(R) (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV)

[Guest guest]

http://www.marketwatch.com/story/sciclone-pharmaceuticals-to-present-at-two-inve\

stor-conferences-in-september-2011-09-01?reflink=MW_news_stmp

press release

Sept. 1, 2011, 7:00 a.m. EDT

SciClone Pharmaceuticals to Present at Two Investor Conferences in September

Rodman & Renshaw Global Investment Conference: Healthcare Track - Monday,

September 12 at 10:50 am ET and China Track - Tuesday, September 13 at 9:35 am

ET; UBS Global Life Sciences Conference on Wednesday, September 21 at 8 am ET

FOSTER CITY, CA, Sep 01, 2011 (MARKETWIRE via COMTEX) -- SciClone

Pharmaceuticals, Inc. /quotes/zigman/77751/quotes/nls/scln SCLN -4.72% today

announced that it will present at two upcoming investor conferences: Rodman &

Renshaw Global Investment Conference, and UBS Global Life Sciences Conference.

SciClone's executives will present a corporate overview and business update at

each conference.

Rodman & Renshaw Global Investment Conference Monday, September 12; 10:50 am ET

(Healthcare track) Tuesday, September 13; 9:35 am ET (China track) New York

City, NY Presenter: Friedhelm Blobel, PhD, President and CEO

UBS Global Life Sciences Conference Wednesday, September 21; 8:00 am ET New York

City, NY Presenter: Titus, Senior Vice President and CFO

To access the live audio webcasts of the presentations, please log on through a

link located in the Investor Relations section of SciClone's website at

www.sciclone.com .

About SciClone SciClone Pharmaceuticals is a revenue-generating, profitable,

China-centric specialty pharmaceutical company with a substantial commercial

business and a product portfolio of therapies for oncology, infectious diseases

and cardiovascular, urological, respiratory, and central nervous system

disorders. SciClone's ZADAXIN® (thymalfasin) is approved in over 30 countries

and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), as a

vaccine adjuvant, and certain cancers according to the approvals we have in

these countries. SciClone markets nearly 20, mostly partnered products in China

besides ZADAXIN, including Depakine®, the most widely prescribed

broad-spectrum anti-convulsant in China; Tritace®, an ACE inhibitor for the

treatment of hypertension; Stilnox®, a fast-acting hypnotic for the short-term

treatment of insomnia (marketed as Ambien® in the US); and Aggrastat®, a

recently-launched intervention cardiology product. On the development side,

SciClone is evaluating SCV-07 in a phase 2b trial for the delay to onset of oral

mucositis in patients with head and neck cancer. SciClone is also pursuing the

registration of several other therapeutic products in China. SciClone is

headquartered in City, California. For additional information, please

visit www.sciclone.com .

Ambien, Depakine, Stilnox and Tritace are registered trademarks of Sanofi S.A.

Aggrastat is a registered trademark of Merck & Co., Inc.

Contact

Ana Kapor

Investors/Media

650.350.4825

akapor@...